

Final Prescribing Information Email, June 20, 2011 - Laviv

From: Zhu, Yao-Yao
Sent: Monday, June 20, 2011 1:53 PM
To: Tull, Lori Cc: Schneider, Bruce
Subject: FW: BLA 125348 Amendment 046 - Final Prescribing Information

Attachments: demographics.doc

-----Original Message-----

From: Zhu, Yao-Yao
Sent: Sunday, June 19, 2011 12:24 AM
To: 'jnovak@cbrintl.com'; Schneider, Bruce; Dana Weinberger Cc: Kevin Hennegan; Lee Buttrill
Subject: RE: BLA 125348 Amendment 046 - Final Prescribing Information

Jeanne,

Please see attached demographics from integrated safety data and from the two pivotal trials (005 and 006). It appears that the upper limit of age in control group in the integrated safety population (79 yo) did not match the upper age in the pivotal trial 006 (81). Please provide an explanation.
Yao-Yao

-----Original Message-----

From: Jeanne Novak [<mailto:jnovak@cbrintl.com>]
Sent: Sunday, June 19, 2011 12:21 AM
To: Schneider, Bruce; Jeanne CBR; Dana Weinberger Cc: Kevin Hennegan; Zhu, Yao-Yao; Lee Buttrill
Subject: Re: BLA 125348 Amendment 046 - Final Prescribing Information

Bruce,

As we look into this and if we have questions can I call you? It would be tomorrow. If so, is there a good number?

Jeanne M. Novak, Ph.D.
CEO and President
Principal Consultant

CBR International Corp.® 7
20-746-1190
720-746-1192 (Fax)
www.cbrintl.com

This electronic transmission (including any and all attachments) is intended solely for the use of the individual or entity to whom it is addressed and may contain information that is privileged and/or confidential. If you are not the intended recipient of this electronic transmission, you are hereby notified that any disclosure, copying or distribution, or the taking of any action in reliance upon the contents of this electronic transmission, is strictly prohibited, and you are further requested to purge this electronic transmission and all copies thereof from your computer system.

Sent wirelessly via BlackBerry from T-Mobile.

-----Original Message-----

From: "Schneider, Bruce" <Bruce.Schneider@fda.hhs.gov>
Date: Sat, 18 Jun 2011 23:42:09
To: 'jnovak@cbrintl.com'>; Dana Weinberger<dweinberger@cbrintl.com>
Cc: Kevin Hennegan<khennegan@cbrintl.com>; Zhu, Yao-Yao<Yao-Yao.Zhu@fda.hhs.gov>; Lee Buttrill<lbuttrill@cbrintl.com>
Subject: RE: BLA 125348 Amendment 046 - Final Prescribing Information

Page Last Updated: 07/20/2011

Note: If you need help accessing information in different file formats, see [Instructions for Downloading Viewers and Players](#).

Language Assistance Available: [Español](#) | [繁體中文](#) | [Tiếng Việt](#) | [한국어](#) | [Tagalog](#) | [Русский](#) | [فېبرعلا](#) | [Kreyòl Ayisyen](#) | [Français](#) | [Polski](#) | [Português](#) | [Italiano](#) | [Deutsch](#) | [日本語](#) | [ىسراف](#) | [English](#)